RU2013124101A - HETEROCYCLIC AMINES AND THEIR APPLICATIONS - Google Patents
HETEROCYCLIC AMINES AND THEIR APPLICATIONS Download PDFInfo
- Publication number
- RU2013124101A RU2013124101A RU2013124101/04A RU2013124101A RU2013124101A RU 2013124101 A RU2013124101 A RU 2013124101A RU 2013124101/04 A RU2013124101/04 A RU 2013124101/04A RU 2013124101 A RU2013124101 A RU 2013124101A RU 2013124101 A RU2013124101 A RU 2013124101A
- Authority
- RU
- Russia
- Prior art keywords
- pyridin
- thiazol
- amino
- methyl
- amine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D269/00—Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups C07D261/00 - C07D267/00
- C07D269/02—Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups C07D261/00 - C07D267/00 having the hetero atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
1. Соединение формулы (I):,или его соль, сложный эфир, амид, или пролекарство,гдепредставляет собой одинарную или двойную связь;W выбран из CH, СН-CH, O, S, NRи CO;Y представляет собой N или CR;Z представляет собой N или C, и Z представляет собой N, если W представляет собой CH, и Y представляет собой CR;Rвыбран из водорода, галогена, OR, CN, NRR, CHOR, необязательно замещенного арила, необязательно замещенного гетероарила, необязательно замещенного неароматического кольца, необязательно замещенного карбоцикла, необязательно замещенного С-Салкила, необязательно замещенного C-Cгалогеналкила, необязательно замещенного C-Cгетероалкила, необязательно замещенного C-Cалкенила, необязательно замещенного C-Cалкинила, COR, SOR, SORи SONRR;Rвыбран из водорода, галогена, OR, необязательно замещенного C-Cалкила, необязательно замещенного C-Cгалогеналкила, необязательно замещенного C-Cгетероалкила, необязательно замещенного C-Cгалогенгетероалкила, необязательно замещенного C-Cалкенила и необязательно замещенного C-Cалкинила;или Rи Rсоединены с образованием необязательно замещенного неароматического кольца;каждый Rнезависимо выбран из необязательно замещенного арила, необязательно замещенного гетероарила и необязательно замещенного неароматического кольца, каждый из которых необязательно конденсирован с замещенным арилом или замещенным гетероарилом, водорода, необязательно замещенного C-Cалкила, необязательно замещенного C-Cгалогеналкила и необязательно замещенного C-Cгетероалкила;каждый Rи Rнезависимо выбран из необязательно замещенного арила, необязательно замещенного гетероарила, необязательно замещенного неароматического кольца, каждый из которых �1. The compound of formula (I) :, or a salt, ester, amide, or prodrug thereof, wherein is a single or double bond; W is selected from CH, CH — CH, O, S, NR, and CO; Y is N or CR ; Z is N or C, and Z is N if W is CH and Y is CR; R is selected from hydrogen, halogen, OR, CN, NRR, CHOR, optionally substituted aryl, optionally substituted heteroaryl, optionally non-aromatic ring, optionally substituted carbocycle, optionally substituted C-C1-6 alkyl, optionally substituted substituted C-C haloalkyl, optionally substituted C-C heteroalkyl, optionally substituted C-Calkenyl, optionally substituted C-Calkynyl, COR, SOR, SOR and SONRR; R selected from hydrogen, halogen, OR, optionally substituted C-Calkyl, optionally substituted C-C haloalkyl, optionally substituted C-C heteroalkyl, optionally substituted C-C haloheteroalkyl, optionally substituted C-Calkenyl and optionally substituted C-C alkynyl; or R and R are connected to form an optionally substituted non-aromatic ring; each R is independently selected from optionally substituted aryl, optionally substituted heteroaryl and optionally substituted non-aromatic ring, each of which is optionally fused to substituted aryl or substituted heteroaryl, hydrogen, optionally substituted C-Calkyl, optionally substituted C-C haloalkyl and optionally substituted C-C heteroalkyl; each R is independently selected from optionally substituted aryl, optionally substituted heteroaryl, optionally substituted non-aromatic ring, each of which
Claims (26)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41568510P | 2010-11-19 | 2010-11-19 | |
US61/415,685 | 2010-11-19 | ||
PCT/US2011/061532 WO2012068546A1 (en) | 2010-11-19 | 2011-11-18 | Heterocycle amines and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017135541A Division RU2017135541A (en) | 2010-11-19 | 2011-11-18 | HETEROCYCLIC AMINES AND THEIR APPLICATIONS |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2013124101A true RU2013124101A (en) | 2014-12-27 |
RU2632900C2 RU2632900C2 (en) | 2017-10-11 |
Family
ID=45094285
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017135541A RU2017135541A (en) | 2010-11-19 | 2011-11-18 | HETEROCYCLIC AMINES AND THEIR APPLICATIONS |
RU2013124101A RU2632900C2 (en) | 2010-11-19 | 2011-11-18 | Heterocyclic amines and their application |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017135541A RU2017135541A (en) | 2010-11-19 | 2011-11-18 | HETEROCYCLIC AMINES AND THEIR APPLICATIONS |
Country Status (14)
Country | Link |
---|---|
US (5) | US9266874B2 (en) |
EP (3) | EP2640708A1 (en) |
JP (3) | JP6005050B2 (en) |
KR (2) | KR101903204B1 (en) |
CN (2) | CN103298792A (en) |
ES (1) | ES2672203T3 (en) |
HK (1) | HK1252165A1 (en) |
HU (1) | HUE037860T2 (en) |
MX (3) | MX344521B (en) |
PL (1) | PL2730564T3 (en) |
PT (1) | PT2730564T (en) |
RS (1) | RS57375B1 (en) |
RU (2) | RU2017135541A (en) |
WO (1) | WO2012068546A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2743716C2 (en) * | 2015-09-18 | 2021-02-24 | Мерк Патент Гмбх | Heteroaryl compounds as irak inhibitors and their application |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2566860B1 (en) * | 2010-05-06 | 2014-09-10 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as gpr119 modulators |
EP2847215A1 (en) * | 2012-05-07 | 2015-03-18 | Synthes GmbH | Methods and devices for treating intervertebral disc disease |
JP6215338B2 (en) * | 2012-11-08 | 2017-10-18 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Bicyclic heterocycle-substituted pyridyl compounds useful as kinase modulators |
EP3049086A4 (en) * | 2013-09-27 | 2017-02-22 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
KR20160106627A (en) * | 2013-12-30 | 2016-09-12 | 라이프에스씨아이 파마슈티컬스, 인크. | Therapeutic inhibitory compounds |
JP6479850B2 (en) | 2014-01-13 | 2019-03-06 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors |
SI3286181T1 (en) | 2015-04-22 | 2021-07-30 | Rigel Pharmaceuticals, Inc. | Pyrazole compounds and method for making and using the compounds |
EP3322409A4 (en) * | 2015-07-15 | 2019-07-24 | Aurigene Discovery Technologies Limited | Substituted aza compounds as irak-4 inhibitors |
WO2017102091A1 (en) | 2015-12-18 | 2017-06-22 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
JOP20180011A1 (en) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | PYRROLO[1,2-b] PYRIDAZINE DERIVATIVES |
RS64411B1 (en) | 2017-03-31 | 2023-09-29 | Aurigene Oncology Ltd | Compounds and compositions for treating hematological disorders |
WO2018234342A1 (en) * | 2017-06-21 | 2018-12-27 | F. Hoffmann-La Roche Ag | Isoindolinone derivatives as irak4 modulators |
US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
EP3684365A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
MX2020003666A (en) | 2017-10-31 | 2020-08-03 | Curis Inc | Compounds and compositions for treating hematological disorders. |
WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
MX2020006812A (en) | 2017-12-26 | 2020-11-06 | Kymera Therapeutics Inc | Irak degraders and uses thereof. |
EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
EP3817748A4 (en) | 2018-07-06 | 2022-08-24 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
TWI721483B (en) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | Pyrrolo[1,2-b]pyridazine derivatives |
SG11202105424PA (en) | 2018-11-30 | 2021-06-29 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
MX2022002292A (en) | 2019-08-30 | 2022-06-02 | Rigel Pharmaceuticals Inc | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations. |
US20230020507A1 (en) * | 2019-10-04 | 2023-01-19 | Parenchyma Biotech Inc. | Compound and use thereof in treating autoimmune diseases |
EP4076520A4 (en) | 2019-12-17 | 2024-03-27 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
EP4146639A1 (en) | 2020-05-06 | 2023-03-15 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
TW202210483A (en) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Crystalline forms of irak degraders |
US20230357271A1 (en) | 2020-09-30 | 2023-11-09 | Asahi Kasei Pharma Corporation | Macrocyclic compound |
AU2020471055B8 (en) | 2020-09-30 | 2023-12-21 | Asahi Kasei Pharma Corporation | Pyrimidine- and nitrogen-containing bicyclic compound |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5542990B2 (en) * | 1972-01-27 | 1980-11-04 | ||
WO1997049704A1 (en) | 1996-06-27 | 1997-12-31 | Janssen Pharmaceutica N.V. | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines |
ES2256969T3 (en) | 1997-11-10 | 2006-07-16 | Bristol-Myers Squibb Company | INHIBITING BENZOTIAZOL PROTEIN TIROSINE QAUINASA COMPOUNDS. |
JP2000086641A (en) * | 1998-09-11 | 2000-03-28 | Kyorin Pharmaceut Co Ltd | 2-substituted benzothiazole derivative and its production |
WO2003082272A1 (en) * | 2002-03-29 | 2003-10-09 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
US20040023978A1 (en) * | 2002-07-24 | 2004-02-05 | Yu Ren | Active salt forms with tyrosine kinase activity |
US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
US20070066577A1 (en) * | 2003-04-03 | 2007-03-22 | Hea Young Park Choo | Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same |
WO2005033105A2 (en) | 2003-09-30 | 2005-04-14 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
US20050084835A1 (en) | 2003-10-16 | 2005-04-21 | The Singing Machine Company, Inc. | Karaoke system with built-in camera |
WO2005044793A2 (en) | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
EP1674466A1 (en) | 2004-12-27 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors |
US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
KR20070052207A (en) * | 2005-11-16 | 2007-05-21 | 주식회사 엘지생명과학 | Novel inhibitors of protein kinase |
CN101360707A (en) * | 2005-11-23 | 2009-02-04 | 利亘制药公司 | Thrombopoietin activity modulating compounds and methods |
MX2008009215A (en) * | 2006-01-17 | 2008-12-10 | Barrier Therapeutics Inc | Treatment of inflammatory disorders with triazole compounds. |
CA2637172A1 (en) * | 2006-01-27 | 2007-08-09 | Array Biopharma Inc. | Pyridin-2-amine derivatives and their use as glucokinase activators |
US20080293785A1 (en) * | 2006-04-11 | 2008-11-27 | Connolly Peter J | Substituted benzothiazole kinase inhibitors |
CN101558059B (en) * | 2006-08-11 | 2014-12-03 | 百时美施贵宝公司 | Hepatitis c virus inhibitors |
AU2007292924A1 (en) * | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
CN101616910A (en) * | 2006-09-07 | 2009-12-30 | 比奥根艾迪克Ma公司 | Indazole derivatives as interleukin 1 receptor associated kinase conditioning agent |
JP2008255024A (en) * | 2007-04-02 | 2008-10-23 | Banyu Pharmaceut Co Ltd | Biarylamine derivative |
US20090258907A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | Compounds useful as inhibitors of rock kinases |
EP2277881A4 (en) * | 2008-04-18 | 2011-09-07 | Shionogi & Co | Heterocyclic compound having inhibitory activity on p13k |
JP2011529086A (en) * | 2008-07-24 | 2011-12-01 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | Contrast agents useful for identifying AD lesions |
JP5177076B2 (en) | 2008-07-28 | 2013-04-03 | 日産自動車株式会社 | Vehicle driving support device and vehicle driving support method |
TWI396689B (en) * | 2008-11-14 | 2013-05-21 | Amgen Inc | Pyrazine derivatives as phosphodiesterase 10 inhibitors |
US9067947B2 (en) * | 2009-01-16 | 2015-06-30 | Universal Display Corporation | Organic electroluminescent materials and devices |
MX2011009033A (en) * | 2009-02-27 | 2011-09-15 | Vertex Pharma | Tri-cyclic pyrazolopyridine kinase inhibitors. |
JP2012520845A (en) * | 2009-03-17 | 2012-09-10 | グラクソ グループ リミテッド | Pyrimidine derivatives used as Itk inhibitors |
JP6073677B2 (en) * | 2009-06-12 | 2017-02-01 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Fused heterocyclic compounds and their use |
WO2011110575A1 (en) * | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
WO2012035055A1 (en) * | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
DK3536685T3 (en) | 2014-04-04 | 2022-03-07 | Pfizer | BICYCLIC-FUSIONED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAQ4 INHIBITORS |
-
2011
- 2011-11-18 RU RU2017135541A patent/RU2017135541A/en unknown
- 2011-11-18 RU RU2013124101A patent/RU2632900C2/en active
- 2011-11-18 EP EP11791162.8A patent/EP2640708A1/en not_active Withdrawn
- 2011-11-18 JP JP2013540089A patent/JP6005050B2/en active Active
- 2011-11-18 RS RS20180735A patent/RS57375B1/en unknown
- 2011-11-18 KR KR1020137015153A patent/KR101903204B1/en active IP Right Grant
- 2011-11-18 EP EP18161665.7A patent/EP3357915A1/en not_active Withdrawn
- 2011-11-18 ES ES14153493.3T patent/ES2672203T3/en active Active
- 2011-11-18 CN CN2011800643922A patent/CN103298792A/en active Pending
- 2011-11-18 KR KR1020187024789A patent/KR20180099933A/en not_active Application Discontinuation
- 2011-11-18 PT PT141534933T patent/PT2730564T/en unknown
- 2011-11-18 HU HUE14153493A patent/HUE037860T2/en unknown
- 2011-11-18 WO PCT/US2011/061532 patent/WO2012068546A1/en active Application Filing
- 2011-11-18 CN CN201810959036.0A patent/CN108864151A/en active Pending
- 2011-11-18 MX MX2013005549A patent/MX344521B/en active IP Right Grant
- 2011-11-18 PL PL14153493T patent/PL2730564T3/en unknown
- 2011-11-18 MX MX2016016899A patent/MX366318B/en unknown
- 2011-11-18 EP EP14153493.3A patent/EP2730564B1/en active Active
-
2013
- 2013-05-16 MX MX2019008122A patent/MX2019008122A/en unknown
- 2013-12-20 US US14/137,318 patent/US9266874B2/en active Active
-
2016
- 2016-01-26 US US15/006,940 patent/US10030034B2/en active Active
- 2016-09-02 JP JP2016171817A patent/JP6316888B2/en active Active
-
2018
- 2018-03-27 JP JP2018059583A patent/JP6726226B2/en active Active
- 2018-06-22 US US16/015,925 patent/US10604533B2/en active Active
- 2018-09-07 HK HK18111558.1A patent/HK1252165A1/en unknown
-
2020
- 2020-01-07 US US16/735,988 patent/US11186593B2/en active Active
-
2021
- 2021-10-28 US US17/513,093 patent/US11773110B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2743716C2 (en) * | 2015-09-18 | 2021-02-24 | Мерк Патент Гмбх | Heteroaryl compounds as irak inhibitors and their application |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2013124101A (en) | HETEROCYCLIC AMINES AND THEIR APPLICATIONS | |
JP2013544256A5 (en) | ||
ES2961577T3 (en) | TANK-binding kinase inhibitor compounds | |
HRP20210094T1 (en) | Method of preparing oxazolo[4,5-b]pyridine and thiazolo[4,5-b]pyridine derivatives as irak4 inhibitors for treating cancer | |
CA2950475C (en) | Indolin-2-one or pyrrolo-pyridin-2-one derivatives | |
AU2016240033B2 (en) | 1-cyano-pyrrolidine compounds as USP30 inhibitors | |
CA2671744A1 (en) | Compounds and compositions as protein kinase inhibitors | |
JP2021514359A (en) | Heterocyclic compounds as kinase inhibitors | |
TW201827428A (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
JP2014521711A5 (en) | ||
RU2018138047A (en) | HETEROCYCLIC SUBSTANCES - AGONISTS GPR119 | |
AU2007214462A1 (en) | PI-3 kinase inhibitors and methods of their use | |
AU2012242777A1 (en) | Compositions and therapeutic uses of IKK-related kinase epsilon and TANKbinding kinase 1 inhibitors | |
CA2962578A1 (en) | Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds | |
JP2013533300A (en) | Inhibitor of breton-type tyrosine kinase | |
JP2013528591A5 (en) | ||
RU2014149684A (en) | Aminoquinazole derivatives and pyridopyrimidine | |
JP2014501269A5 (en) | ||
IL274198B2 (en) | Use of nox inhibitors for treatment of cancer | |
CA3211347A1 (en) | Indazole based compounds and associated methods of use | |
HRP20221454T1 (en) | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds | |
AU2019379213A1 (en) | Six-membered fused with six-membered heterocyclic compound and uses thereof serving as protein receptor kinase inhibitor | |
RU2022107496A (en) | Heterocyclic pyrazole derivatives as receptor tyrosikinase type III inhibitors | |
CA3223769A1 (en) | Bruton's tyrosine kinase and mutant degrader, composition and application thereof | |
JPWO2020203609A5 (en) |